137 related articles for article (PubMed ID: 27470393)
1. IGF1R and c-met as therapeutic targets for colorectal cancer.
Shali H; Ahmadi M; Kafil HS; Dorosti A; Yousefi M
Biomed Pharmacother; 2016 Aug; 82():528-36. PubMed ID: 27470393
[TBL] [Abstract][Full Text] [Related]
2. Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?
Inno A; Di Salvatore M; Cenci T; Martini M; Orlandi A; Strippoli A; Ferrara AM; Bagalà C; Cassano A; Larocca LM; Barone C
Clin Colorectal Cancer; 2011 Dec; 10(4):325-32. PubMed ID: 21729677
[TBL] [Abstract][Full Text] [Related]
3. The c-Met receptor: Implication for targeted therapies in colorectal cancer.
Safaie Qamsari E; Safaei Ghaderi S; Zarei B; Dorostkar R; Bagheri S; Jadidi-Niaragh F; Somi MH; Yousefi M
Tumour Biol; 2017 May; 39(5):1010428317699118. PubMed ID: 28459362
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous inhibition of IGF1R and EGFR enhances the efficacy of standard treatment for colorectal cancer by the impairment of DNA repair and the induction of cell death.
Oberthür R; Seemann H; Gehrig J; Rave-Fränk M; Bremmer F; Halpape R; Conradi LC; Scharf JG; Burfeind P; Kaulfuß S
Cancer Lett; 2017 Oct; 407():93-105. PubMed ID: 28823963
[TBL] [Abstract][Full Text] [Related]
5. Lessons to Learn for Adequate Targeted Therapy Development in Metastatic Colorectal Cancer Patients.
Oliveres H; Pesántez D; Maurel J
Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34065119
[TBL] [Abstract][Full Text] [Related]
6. The potential therapeutic and prognostic impacts of the c-MET/HGF signaling pathway in colorectal cancer.
Parizadeh SM; Jafarzadeh-Esfehani R; Fazilat-Panah D; Hassanian SM; Shahidsales S; Khazaei M; Parizadeh SMR; Ghayour-Mobarhan M; Ferns GA; Avan A
IUBMB Life; 2019 Jul; 71(7):802-811. PubMed ID: 31116909
[TBL] [Abstract][Full Text] [Related]
7. Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells.
Troiani T; Martinelli E; Napolitano S; Vitagliano D; Ciuffreda LP; Costantino S; Morgillo F; Capasso A; Sforza V; Nappi A; De Palma R; D'Aiuto E; Berrino L; Bianco R; Ciardiello F
Clin Cancer Res; 2013 Dec; 19(24):6751-65. PubMed ID: 24122793
[TBL] [Abstract][Full Text] [Related]
8. Expression of the HGF/SF receptor, c-met, and its ligand in human colorectal cancers.
Hiscox SE; Hallett MB; Puntis MC; Nakamura T; Jiang WG
Cancer Invest; 1997; 15(6):513-21. PubMed ID: 9412656
[TBL] [Abstract][Full Text] [Related]
9. IGF1R signalling and its inhibition.
Riedemann J; Macaulay VM
Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S33-43. PubMed ID: 17259557
[TBL] [Abstract][Full Text] [Related]
10. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.
Sachdev D; Li SL; Hartell JS; Fujita-Yamaguchi Y; Miller JS; Yee D
Cancer Res; 2003 Feb; 63(3):627-35. PubMed ID: 12566306
[TBL] [Abstract][Full Text] [Related]
11. Quantitative phospho-proteomic profiling of hepatocyte growth factor (HGF)-MET signaling in colorectal cancer.
Organ SL; Tong J; Taylor P; St-Germain JR; Navab R; Moran MF; Tsao MS
J Proteome Res; 2011 Jul; 10(7):3200-11. PubMed ID: 21609022
[TBL] [Abstract][Full Text] [Related]
12. Radiation stimulates HGF receptor/c-Met expression that leads to amplifying cellular response to HGF stimulation via upregulated receptor tyrosine phosphorylation and MAP kinase activity in pancreatic cancer cells.
Qian LW; Mizumoto K; Inadome N; Nagai E; Sato N; Matsumoto K; Nakamura T; Tanaka M
Int J Cancer; 2003 May; 104(5):542-9. PubMed ID: 12594808
[TBL] [Abstract][Full Text] [Related]
13. Correlation of clinicopathological parameters with HGF, c-Met, EGFR, and IGF-1R expression in uveal melanoma.
Topcu-Yilmaz P; Kiratli H; Saglam A; Söylemezoglu F; Hascelik G
Melanoma Res; 2010 Apr; 20(2):126-32. PubMed ID: 20061986
[TBL] [Abstract][Full Text] [Related]
14. Transcriptional targets of hepatocyte growth factor signaling and Ki-ras oncogene activation in colorectal cancer.
Seiden-Long IM; Brown KR; Shih W; Wigle DA; Radulovich N; Jurisica I; Tsao MS
Oncogene; 2006 Jan; 25(1):91-102. PubMed ID: 16158056
[TBL] [Abstract][Full Text] [Related]
15. Isolation and characterization of anti c-met single chain fragment variable (scFv) antibodies.
Qamsari ES; Sharifzadeh Z; Bagheri S; Riazi-Rad F; Younesi V; Abolhassani M; Ghaderi SS; Baradaran B; Somi MH; Yousefi M
J Immunotoxicol; 2017 Dec; 14(1):23-30. PubMed ID: 28090795
[TBL] [Abstract][Full Text] [Related]
16. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors.
Burgess T; Coxon A; Meyer S; Sun J; Rex K; Tsuruda T; Chen Q; Ho SY; Li L; Kaufman S; McDorman K; Cattley RC; Sun J; Elliott G; Zhang K; Feng X; Jia XC; Green L; Radinsky R; Kendall R
Cancer Res; 2006 Feb; 66(3):1721-9. PubMed ID: 16452232
[TBL] [Abstract][Full Text] [Related]
17. [MET signalling pathway and its therapeutic implications in gastrointestinal cancers].
Zaanan A; Laurent-Puig P; Taieb J
Bull Cancer; 2014 Jan; 101(1):25-30. PubMed ID: 24445683
[TBL] [Abstract][Full Text] [Related]
18. c-Met, epidermal growth factor receptor, and insulin-like growth factor-1 receptor are important for growth in uveal melanoma and independently contribute to migration and metastatic potential.
Wu X; Zhou J; Rogers AM; Jänne PA; Benedettini E; Loda M; Hodi FS
Melanoma Res; 2012 Apr; 22(2):123-32. PubMed ID: 22343486
[TBL] [Abstract][Full Text] [Related]
19. Targeting the MET gene for the treatment of non-small-cell lung cancer.
Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
[TBL] [Abstract][Full Text] [Related]
20. Hepatocyte growth factor/MET and CD44 in colorectal cancer: partners in tumorigenesis and therapy resistance.
Joosten SPJ; Spaargaren M; Clevers H; Pals ST
Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188437. PubMed ID: 32976979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
